Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development AdAlta Ltd Ambrx Inc Biokine Therapeutics Ltd BioLineRx Ltd Bristol-Myers Squibb Co Eli Lilly and Co FairJourney Biologics SA GlycoMimetics Inc Pfizer Inc Polyphor AG Tactiva Therapeutics LLC TaiGen Biotechnology Co Ltd Upsher-Smith Laboratories Inc X4 Pharmaceuticals Inc C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles AD-214 - Drug Profile AM-3114 - Drug Profile balixafortide - Drug Profile BKT-300 - Drug Profile BL-8040 - Drug Profile burixafor - Drug Profile GMI-1359 - Drug Profile HPH-112 - Drug Profile hz-515H7 - Drug Profile LY-2510924 - Drug Profile mavorixafor - Drug Profile Monoclonal Antibodies to Antagonize CXCR4 for Unspecified Indication - Drug Profile Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile Oncolytic Virus to Antagonize CXCR4 for Oncology - Drug Profile PF-06747143 - Drug Profile POL-5551 - Drug Profile Protein to Agonize CXCR4 for Inflammation - Drug Profile PTX-9908 - Drug Profile Q-122 - Drug Profile Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile Small Molecule to Antagonize CXCR4 for Oncology - Drug Profile ulocuplumab - Drug Profile USL-311 - Drug Profile X-4P002 - Drug Profile X-4P003 - Drug Profile X4-136 - Drug Profile C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones Featured News & Press Releases Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indications, H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by AdAlta Ltd, H1 2019 Pipeline by Ambrx Inc, H1 2019 Pipeline by Biokine Therapeutics Ltd, H1 2019 Pipeline by BioLineRx Ltd, H1 2019 Pipeline by Bristol-Myers Squibb Co, H1 2019 Pipeline by Eli Lilly and Co, H1 2019 Pipeline by FairJourney Biologics SA, H1 2019 Pipeline by GlycoMimetics Inc, H1 2019 Pipeline by Harmonic Pharma, H1 2019 Pipeline by Pfizer Inc, H1 2019 Pipeline by Polyphor AG, H1 2019 Pipeline by Que Oncology Inc, H1 2019 Pipeline by Tactiva Therapeutics LLC, H1 2019 Pipeline by TaiGen Biotechnology Co Ltd, H1 2019 Pipeline by Upsher-Smith Laboratories Inc, H1 2019 Pipeline by X4 Pharmaceuticals Inc, H1 2019 Dormant Products, H1 2019 Discontinued Products, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Top 10 Routes of Administration, H1 2019 Number of Products by Stage and Top 10 Routes of Administration, H1 2019 Number of Products by Top 10 Molecule Types, H1 2019 Number of Products by Stage and Top 10 Molecule Types, H1 2019

AdAlta Ltd Ambrx Inc Biokine Therapeutics Ltd BioLineRx Ltd Bristol-Myers Squibb Co Eli Lilly and Co FairJourney Biologics SA GlycoMimetics Inc Harmonic Pharma Pfizer Inc Polyphor AG Que Oncology Inc Tactiva Therapeutics LLC TaiGen Biotechnology Co Ltd Upsher-Smith Laboratories Inc X4 Pharmaceuticals Inc